New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...
Legend Biotech has managed to remove Genscript Biotech as its majority shareholder, just as the former parent’s Chinese ...
In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Legend Biotech (LEGN – Research ...
Hosted on MSN12d
Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to TradeLegend Biotech Corporation Sponsored ADR (LEGN) closed the last trading session at $43.95, gaining 0.9% over the past four ...
On Monday, Legend Biotech Corp (LEGN) stock saw a modest uptick, ending the day at $45.3 which represents a slight increase of $0.56 or 1.25% from the prior close of $44.74. The stock opened at $44.96 ...
SOMERSET, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader ...
The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J's Carvykti has in other ...
Legend Biotech has reduced Genscript Biotech's control, lowering its voting power below 50%, amid growing US scrutiny of ...
AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...
Zacks.com on MSN1d
Gilead Science to Report Q3 Earnings: What's in the Cards?Biotech giant Gilead Sciences, Inc. GILD is scheduled to report third-quarter 2024 results on Nov. 6, after market close. The ...
The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars.
Viking Therapeutics (VKTX) stock is reversing gains despite earlier announcing strong results for its experimental obesity pill ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback